L Number	Hits	Search Text	DB	Time stamp
1 Number		2D or two adj dimensional	USPAT;	2003/09/29 14:30
1	220407	20 of two adj dimensional	EPO; JPO;	2000,00,20 2000
			DERWENT;	
	1		IBM TDB	
2	2	2d-fingerprint	USPAT;	2003/09/29 14:34
-		1 La IIII Garpanio	EPO; JPO;	
			DERWENT;	
		, ,	IBM TDB	
3	5	2d-structure	USPAT;	2003/09/29 14:38
			EPO; JPO;	
			DERWENT;	
		•	IBM TDB	
4 -	7007	pharmacokinetic	USPAT;	2003/09/29 14:39
		•	EPO; JPO;	
			DERWENT;	
			IBM TDB	
5	941	(2D or two adj dimensional) and	USPĀT;	2003/09/29 14:39
		pharmacokinetic	EPO; JPO;	
			DERWENT;	
	İ		IBM_TDB	
6	35	structural adj descriptor	USPAT;	2003/09/29 14:39
		,	EPO; JPO;	
			DERWENT;	<u> </u>
			IBM_TDB	
7	2		USPAT;	2003/09/29 14:41
		pharmacokinetic) and (structural adj	EPO; JPO;	
		descriptor)	DERWENT;	
			IBM_TDB	0000/00/00
8	12975	descriptor	USPAT;	2003/09/29 14:41
			EPO; JPO;	
			DERWENT;	
_	_	(/2D on two add dimensional) and	IBM_TDB USPAT;	2003/09/29 14:58
9	6	'\[ \] =	EPO; JPO;	2003/03/23 14:38
		pharmacokinetic) and descriptor	DERWENT;	
		·	IBM TDB	
10	9	OSPR	USPAT;	2003/09/29 15:09
10		Anti	EPO; JPO;	
			DERWENT;	
			IBM TDB	
11	l 0	predict\$ near phamacokinetic	USPAT;	2003/09/29 15:10
		1	EPO; JPO;	
			DERWENT;	
			IBM TDB	
12	0	predict\$ same phamacokinetic	USPĀT;	2003/09/29 15:10
			EPO; JPO;	
			DERWENT;	
			IBM_TDB	
14	29		USPĀT;	2003/09/29 15:30
		pharmacokinetic) and (predict\$ same	EPO; JPO;	
		pharmacokinet\$)	DERWENT;	
			IBM_TDB	
15	6	1	USPAT;	2003/09/29 15:30
		pharmacokinet\$)	EPO; JPO;	
			DERWENT;	
			IBM_TDB	0000/00/00 15 01
13	392	predict\$ same pharmacokinet\$	USPAT;	2003/09/29 15:31
		·	EPO; JPO;	
			DERWENT;	
	<u> </u>		IBM_TDB	

	ט	1	Document ID	Issue Date	Page s	Title	Current OR ,	Current XRef
371	⊠		EP 1167969 A	2003041	14	Prediction of pharmacokinetic properties of molecules such as drug absorption for drug discovery, comprises analyzing 2D-fingerprint of molecule obtained from 2D-structure, to yield structure-property relationship		
372	⊠		GB 2361922 A	2001110	16	Novel rat G-protein coupled receptor AXOR29 polypeptide and polynucleotide for identifying agonists and antagonists		
373	⊠		US 200200225 99 A	2003010 2	26	Modifying multiple drug resistance or drug pharmacokinetics e.g. drug intestinal efflux, catabolism, oral absorption or biliary excretion, by altering activity of SXR on expression levels of CYP2C8 or MDR1		
374		•	US 200200648 14 A	2001061 4	16	Novel Beagle Orexin 1 receptor polypeptides and polynucleotides for identifying modulators for use in preventing, and treating psychotic and neurological disorders, asthma, cancer, diabetes and microbial infections		

	ı <u></u>				r			ſ			
	Retriev al Classif	Inventor	s	С	P	2	3	4	5	Image Doc. Displayed	PT
371		HATTORI, K et al.			0					US 20030069698	
372		ELSHOURBAGY, N et al.								US 20020045214	
373		FORMAN, B et al.								US 20020022599	
374	-	ELLIS, C E								US 20020064814	

		,			1			
	ט	1	Document ID	Issue Date	Page s	Title	Current OR	Current XRef
375	⊠	ı —	WO 200,140304 A	2001060 7	35	Novel cynomolgous monkey orexin 2 receptor polypeptide and polynucleotides encoding them, useful for preventing or treating pain, cancers, diabetes, obesity, anorexia, bulemia, asthma, Parkinson's disease migraine		
376	⊠		WO 200136480 A	2001052 5	34	Novel G-protein coupled receptor polypeptide, polynucleotide for identifying modulators that are useful for treating cancer, infections, psychotic, neurological disorders, asthma, allergies and myocardial infarction		
377	⊠	1	WO 200132889 A	2001051	34	Novel murine serine/threonine kinase polypeptides and polynucleotides for identifying agonists, antagonists useful for treating anemia, cancer, rheumatoid arthritis, psoriasis, psychotic and neurological disord		

	Retriev al Classif	Inventor	s	С	P	2	3	4	5	Image Doc. Displayed	РТ
375		ELLIS, C E					0			WO 200140304 A1	
376		GATTU, M et al.								WO 200136480 A1	
377		CREASY, C L et al.					٥			WO 200132889 A1	

	υ	1	Document ID	Issue Date	Page s	Title	Current OR	Current XRef
378	⊠		WO 200126641 A	2003032 5	33	Use of (2S,3S,5R)-2-(3,5-d ifluorophenyl)-3,5- dimethyl-2-morphino l, to treat obesity, cause weight loss, maintain weight loss, prevent weight gain, affect body fat composition, suppress appetite and inhibit food cr		
379	⊠		WO 200111022 A	2001021 5	35	New mouse G-protein coupled receptor EDG3 polypeptide, useful for screening (ant) agonists for treating cancer, diabetes, asthma, myocardial infarction, bone and neurological disorders		
380	Ø	Variationalistation retainer and retainer and retainer at the	US 6432678 B	2001012 5	11	Macaca cynomolgus interleukin-18 polypeptides, useful for screening agonist or antagonist that are useful for treating cancer and autoimmune diseases		
381			WO 200103668 A	2003020	43	Liposomal composition for pulmonary administration, useful for treating nausea, loss of appetite, glaucoma, seizure, multiple sclerosis or pain, comprises a cannabinoid or a cannabimimetic agent		

	Retriev al Classif	Inventor	s	С	P	2	3	4	5	Image Doc. Displayed	PT
378		MATTHEWS, J E et al.								WO 200126641 A2	
379		ELSHOURBAGY, N A et al.								WO 200111022 A1	
380		TAYLOR, A H et al.								US 6432678	
381		HUNG, O et al.								WO 200103668 A1	

	ט	1	Document ID	Issue Date	Page s	Title	Current OR	Current XRef
382			US 200200190 19 A	2003012	22	New method for assaying a drug candidate with a biosensor having one or more surface-bound biomolecules where the absorption, distribution, metabolism, or excretion data may predict the behavior and fate of the drug candidate		
383	Ø		WO 200069441 A	2002122 4	30	Use of agent isolated from Caribbean tunicae Ecteinascidia turbinata in the treatment of cancer in humans e.g. sarcoma and breast cancer		
384	×		WO 200070048 A	2000112	32	Murine organic anion transporter 6 polypeptide, useful for identifying agonists/antagonist s that are useful in treatment of cancer, kidney disease, autoimmune disease, inflammation and cardiovascular disease		
385	Ø		WO 200061785 A	2000101	27	Novel monkey cathepsin K polypeptide for screening for agonist and antagonist which are useful in treatment of osteoporosis, arthritis, cancer, Paget's disease and other home diseases		

		,									
	Retriev al Classif	Inventor	ធ	U	P	2	3	4	5	Image Doc. Displayed	PT
382		HAEMAELAEINEN, M et al.	⊠.							US 20020019019	
383		CVITKOVIC, E et al.								WO 200069441 A1	
384		ELLENS, H et al.								WO 200070048 A1	
385		FIELD, J								WO 200061785 A2	

	U	1	Document	Issue	Page	Title	Current	Current
	0	_	ID	Date	s	licie	OR	XRef
386	Ø		WO 200055202 A	2000092	29	Novel Bos taurus Frazzled polypeptides and nucleotides encoding them, useful for treating inflammation, arthritis, acquired immunodeficiency syndrome (AIDS) and Alzheimer's diseases		
387	Ø		WO 200052024 A	2000090 8	37	OATP6 polypeptides and polynucleotides encoding them, useful for treating cancer, inflammation, cardiovascular disease, central nervous system disorders, autoimmune disease, kidney or liver disease		
388			US 200200105 50 A	2003040	93	Computer-implemente d method for predicting a pharmacokinetic property of a target compound in an anatomical segment of a target mammalian system		
389	Ø		US 6045815 A	2002102 4	28	Parenterally acceptable, non-toxic antifungal formulation - comprises pimaricin, useful against Fusarium, Aspergillus and Candida especially in immuno-compromised patients		,

	Date/					··I		$\overline{}$		<u> </u>		— ·
:	Retriev al Classif	Inventor	ន	C	P	2	3	4	5		played	PT
386		JAMES, I E et al.								WO 20 A1	0055202	
387		ELLENS, H et al.								WO 20 A1	0052024	
388		GRASS, G M et	×							US 65	42858	
389		ANAISSIE, E J et al.								US 60	45815	

			4							
	υ	1	Document ID	Issue Date	Page s	Title	Current OR	Current XRef		
390	Ø		WO 9849308 A	1998110 5	54	New variants of nerve growth factor able to bind trkC - contain specified mutations and have multiple neurotrophic activities in a single molecule, used for treating, e.g. peripheral neuropathy				
391	⊠		EP 691958 B	1994101 3	7	(S)-alpha-phenyl-2- pyridine:ethan-amin e benzoate - useful in the treatment of neuro-degenerative disorders, as an anti-convulsant and neuro-protective agent				
392	⊠		EP 383579 A	1990082	25	New N-phenyl-N-acyl-1-s ubstd4-amino-pipe ridine derivs useful as analgesic agents with short duration of				

•

			<del></del>						-(8		<del></del>
	Retriev al Classif	Inventor	s	С	P	2	3	4	5	Image Doc. Displayed	PT
390		PRESTA, L G et al.								WO 9849308 A1	
391		MATHISEN, D et al.								EP 691958 B1	
392		BRACKEEN, M F et al.							□	US 5019583	

•

	ט	1	Document ID	Issue Date	Page s	Title	Current OR	Current XRef
1	×		US 6615141 B1	2003090	49	Database system for predictive cellular bioinformatics	702/19	382/133; 435/6
2	×		US 6613784 B1	2003090	20	Nitroxyderivatives having antinflammatory, analgesic and antithrombotic activity	514/357	546/334; 546/335
3	⊠		US 6610702 B2	2003082	46	Ammonium salts of inositol hexaphosphate, and uses thereof	514/305	514/311; 514/415; 546/133; 546/164; 548/494
4	Ø		US 6610675 B1	2003082	44	Inactive metabolite approach to soft drug design	514/178	514/169; 552/610
5	Ø		US 6605302 B2	2003081	15	Drug delivery device containing oseltamivir and an H1 antagonist	424/473	
6			US 6605272 B2	2003081	103	Methods of using zalphall ligand	424/85.2	424/169. 1; 424/173. 1; 424/174. 1; 424/85.1; 514/12;
7	×		US 6605072 B2	2003081 2	22	System and method for adaptive drug delivery	604/503	
8	⊠		US 6602892 B1	2003080	29	Methods for nicotine replacement dosage determination	514/343	436/106, 436/816, 436/901, 600/300, 702/19
9	⊠		US 6602664 B2	2003080	31	3'-azido-2',3'-dide oxyuridine in an anti-HIV effectiveness test protocol	435/6	514/51; 536/28.2
10	⊠		US 6599913 B1	2003072	13	Treating allergic and inflammatory conditions	514/290	
11	×		US 6599281 B1	2003072	22	System and method for adaptive drug delivery	604/503	

	Retriev									Image Doc.	
	al Classif	Inventor	ធ	U	P	2	3	4	5	Displayed	PT
1		Sabry, James H. et al.								US 6615141	
2		Benedini, Francesca et al.		۵	О					US 6613784	
3		Lehn, Jean-Marie et al.								US 6610702	
4		Bodor, Nicholas S.	0							US 6610675	
5		Faour, Joaquina et al.								US 6605302	
6		Novak, Julia E. et al.								US 6605272	
7		Struys, Michel et al.								US 6605072	
8		Sachs, David P. L.								US 6602892	
9		Schinazi, Raymond F. et al.								US 6602664	
10		Johnson, William W. et al.								US 6599913	0
11		Struys, Michel et al.								US 6599281	

	U	1	Document ID	Issue Date	Page s	Title	Current OR	Current XRef
12	Ø		US 6589996 B2	2003070	8	Treatment of disorders relating to the serotonergic system	514/648	514/645; 514/657; 514/661
13	⊠	ū	US 6586398 B1	2003070	30	Chemically modified novel erythropoietin stimulating protein compositions and methods	514/12	435/69.4 ; 514/2; 514/8; 530/324; 530/350; 530/395; 530/397; 530/399;
14	×		US 6586392 B2	2003070	31	Conjugates of antiviral proteins or peptides and virus or viral envelope glycoproteins	514/2	424/160. 1; 424/185. 1; 424/186. 1; 424/192. 1; 424/193. 1; 424/194. 1; 435/69.1 ; 435/69.7 ; 514/12; 514/13; 514/14; 514/14; 514/44; 514/8; 530/350; 530/395; 530/402;
15	Ø		US 6586175 B1	2003070	50	Genotyping the human UDP-glucuronosyltra nsferase 2B7	435/6	435/91.2 ; 536/23.1 ;
16	⊠		US 6579895 B2	2003061	15	Use of a celecoxib composition for fast pain relief	514/406	514/263. 32; 514/282; 514/317
17	⊠		US 6579452 B1	2003061	50	Integrated monolithic microfabricated electrospray and liquid chromatography system and method	210/198. 2	204/600; 210/243; 210/656; 210/748; 250/288

	Retriev al Classif	Inventor	s	С	P	2	3	4	5		mage Doc. Displayed	PT
12		Maki-Ikola, Outi et al.								US	6589996	
13		Kinstler, Olaf et al.								US	6586398	
14		Boyd, Michael R.								US	6586392	
15		Galvin, Margaret et al.								US	6586175	
16		Karim, Aziz et al.								US	6579895	
17		Moon, James E. et al.								us	6579452	

	ט	1	Document ID	Issue Date	Page s	Title	Current OR	Current XRef
18	Ø		US 6569432 B1	2003052 7	170	Prostate-specific membrane antigen and uses thereof	424/185. 1	424/277. 1; 530/350
19	⊠		US 6569324 B1	2003052	50	Integrated monolithic microfabricated electrospray and liquid chromatography system and method	210/198. 2	204/600; 210/243; 210/656; 210/748; 250/288
20	⊠		US 6566108 B1	2003052	42	Expression of functional cytochrome P450 monooxygenase system in	435/189	424/94.2 ; 435/252. 33; 435/320.
21	Ø		US 6565859 B1	2003052	8	Galenical formulations	424/400	514/11; 514/291; 514/941
22	×		US 6565827 B1	2003052	28	Radioimmunotherapy of lymphoma using anti-CD20 antibodies	424/1.49	424/1.53; 424/174. 1; 530/388. 73; 530/391. 3;
23			US 6563111 B1	2003051	50	Integrated monolithic microfabricated electrospray and liquid chromatography system and method	250/288	250/281; 250/282
24			US 6562616 B1	2003051	53	Methods and devices for cell culturing and organ assist systems	435/293. 1	435/293. 2; 435/297. 2; 435/370; 435/395; 604/5.04
25			US 6558929 B2	2003050	34	PCR reaction mixture for fluorescence-based gene expression and gene mutation analyses	435/91.1	435/6; 435/91.2
26	⊠		US 6558692	2003050 6	20	Over-coated chewing gum formulations	424/440	424/441; 426/5

	Retriev al Classif	Inventor	S	С	P	2	3	4	5		mage Doc. Displayed	PT
18		Israeli, Ron S. et al.								US	6569432	
19		Moon, James E. et al.								US	6569324	
20		Wolf, Charles Roland et al.								US	6566108	
21		Fricker, Gerd et al.							0	US	6565859	
22		Kaminski, Mark S. et al.								US	6565827	
23		Moon, James E. et al.								US	6563111	
24		Toner, Mehmet et al.		0						US	6562616	
25		Thum, Thomas et al.					0			US	6558929	
26		Ream, Ronald L. et al.								us	6558692	

,	ט	1	Document ID	Issue Date	Page s	Title	Current OR	Current XRef
27	⊠	0	US 6552010 B1	2003042	15	Treatment of SLE with dehydroepiandroster one	514/177	514/170; 514/171
28	⊠		US 6551790 B2	2003042	14	Process for glucuronidation screening	435/15	435/18; 435/968
29	⋈		US 6548484 B1	2003041	25	Pharmaceutical dopamine glycoconjugate compositions and methods of their preparation	514/25	536/17.9
30	×		US 6542858 B1	2003040	93	Pharmacokinetic-bas ed drug design tool and method	703/2	702/19; 703/11
31	⊠		US 6541508 B2	2003040	22	Taxane prodrugs	514/449	528/421; 549/510; 549/511
32	×		US 6538174 B2	2003032	48	Animal model for transplantation	800/9	424/93.1; 424/93.2; 424/93.7; 800/10; 800/14; 800/15;
33	×		US 6537983 B1	2003032	24	Anti-inflammatory androstane derivatives	514/172	424/45; 514/169; 514/171; 514/177; 540/107; 540/108; 540/110; 540/112; 540/114; 540/115
34			US 6531448 B1	2003031	41	Insoluble compositions for controlling blood glucose	514/3	424/491; 514/314; 514/4; 530/303; 530/304; 530/345
35	⊠		US 6528640 B1	2003030	70	Synthetic ribonucleic acids with RNAse activity	536/25.1	536/23.1 ; 536/24.3

	Retriev al Classif	Inventor	s	С	P	2	3	4	5		ge Doc. splayed	PT
27		Schwartz, Kenneth E. et al.								US 6	552010	
28		Trubetskoy, Olga et al.								US 6	551790	
29		Christian, Samuel T.								US 6	548484	
30		Grass, George M. et al.								US 6	542858	
31		Ekwuribe, Nnochiri N. et al.					ņ			US 6	541508	
32		Turner, John Harvey								US 6	538174	
33		Biggadike, Keith et al.								US 6	537983	
34		Brader, Mark Laurence								US 6	531448	
35		Beigelman, Leonid et al.								US 6	528640	

	U	1	Document ID	Issue Date	Page s	Title	Current OR	Current XRef
36		-	` US 6524583 B1	2003022	108	Antibody methods for selectively inhibiting VEGF	424/145. 1	424/133. 1; 424/135. 1; 424/141. 1; 530/387. 1; 530/388. 1; 530/388. 25; 530/888. 25; 530/864; 530/865; 530/866
37	Ø		US 6514995 B1	2003020	23	Enediyne compounds and methods related thereto	514/332	546/2; 546/264
38	Ø		US 6512136 B1	2003012	11	Substituted 2-phenyl-1-(3,4-dih ydroxy-5-nitropheny 1)-1-ethanones, their use in the treatment of some central and peripheral nervous system disorders and pharmaceutical compositions	560/108	560/136; 564/299; 564/300
39	⊠		US 6511678 B2	2003012	20	Containing them  Controlled release formulation of divalproex sodium	424/464	424/465; 424/468; 424/470; 424/489; 424/499
40	Ø		US 6503906 B1	2003010	15	Method for optimizing ciprofloxacin treatment of anthrax-exposed patients according to the patient's characteristics	, 514/253. 05	514/253. 07; 514/253. 08; 514/885
41	Ø		US 6503894 B1	2003010 7	76	Pharmaceutical composition and method for treating hypogonadism	514/178	514/177

	Retriev al Classif	Inventor	S	C	P	2	3	4	5		mage Doc. Displayed	РТ
36		Thorpe, Philip E. et al.		0	0				О	US	6524583	
37		Zaleski, Jeffrey M. et al.								ບຣ	6514995	
38		Benes, Jan et al.								US	6512136	
39		Qiu, Yihong et al.					İ			US	6511678	
40		Lee, Ren-Jin									6503906	
41		Dudley, Robert E. et al.								US	6503894	

	ָד	1	Document ID	Issue Date	Page s	Title	Current OR	Current XRef
42	⊠		US 6498033 B1	2002122	31	Lentiviral vectors	435/320. 1	435/455; 435/456; 435/69.1; 435/91.3; 435/91.3 1; 435/91.4; 536/23.1
43	Ø		US 6491893 B1	2002121	10	Compounds for targeting and imaging infection and inflammation	424/1.41	424/1.69 ; 424/1.85 ;
44	⊠		US 6489289 B2	2002120 3	16	Method for establishing a dosage plan for thrombin inhibitors	514/2	435/39; 514/12; 514/56; 530/324; 530/380; 530/381
45	Ø		US 6486124 B2	2002112	6	Cyclosporin compositions and process therefor	514/11	
46	⊠	<b>-</b>	US 6479236 B2	2002111	47	Genotyping the human UDP-glucuronosyltra nsferase 1 (UGT1)	435/6	536/23.1 ; 536/24.3 ;
47	×		US 6468967 B1	2002102	14	Methods for administration of antibiotics	514/9	514/11; 530/317
48	⊠		US 6465426 B2	2002101	33	Insoluble insulin compositions	514/3	424/491; 514/4; 530/300; 530/303; 530/304; 530/345
49	Ø		US 6465003 B2	2002101	21	Over-coated chewing gum formulations	424/440	424/439; 424/441; 424/464; 426/5
50			US 6464866 B2	2002101	52	Integrated monolithic microfabricated electrospray and liquid chromatography system and method	210/198. 2	204/600; 210/243; 210/656; 210/748; 250/288

	Retriev al Classif	Inventor	s	С	P	2	3	4	5		mage Doc. Displayed	PT
42		Dropulic, Boro et al.								US	6498033	
43		Babich, John W.								US	6491893	
44		Nortersheuser, Peter et al.								US	6489289	
45		Olbrich, Matthias et al.		□						US	6486124	
46		Penny, Laura et al.								US	6479236	
47		Oleson, Jr., Frederick B. et al.								us	6468967	
48		Brader, Mark Laurence								US	6465426	
49		Ream, Ronald L. et al.								US	6465003	
50		Moon, James E. et al.								US	6464866	

	σ	1	Document ID	Issue Date	Page s	Title	Current OR	Current XRef
51	⊠		US 6461516 B2	2002100	52	Integrated monolithic microfabricated electrospray and liquid chromatography system and method	210/656	204/600; 210/198. 2; 210/243; 210/748; 250/288; 436/161
52	×		US 6458976 B1	2002100	18	Taxoid anti-tumor agents, pharmaceutical compositions, and treatment methods	549/510	549/511
53	⊠		US 6458924 B2	2002100 1	128	Derivatives of GLP-1 analogs	530/324	530/345
54	× ×		US 6455518 B2	2002092	9	Pharmaceutical compositions for the treatment of transplant rejection, autoimmune or inflammatory conditions comprising cyclosporin a and 40-0-(2-hydroxyethy 1)-rapamycin	514/183	514/31; 514/514; 514/516
55	⊠		US 6455043 B1	2002092 4	13	Combination therapies for B-cell lymphomas comprising administration of anti-CD20 antibody	424/155. 1	424/1.49; 424/133. 1; 424/143. 1; 424/144. 1; 424/156. 1;
56	⊠		US 6454938 B2	2002092 4	53	Integrated monolithic microfabricated electrospray and liquid chromatography system and method	210/198. 2	204/600; 210/243; 210/656; 210/748; 250/288
57	⊠		US 6448287 B1	2002091 0	5	Treatment of cancer using lipoic acid in combination with ascorbic acid	514/440	514/474

									-(		
	Retriev al Classif	Inventor	ន	С	P	2	3	4	5	Image Doc. Displayed	РТ
51		Moon, James E. et al.				, _				US 6461516	
52		Ojima, Iwao								US 6458976	
53		Knudsen, Liselotte Bjerre et al.								US 6458924	
54		Zenke, Gerhard et al.								US 6455518	
55		Grillo-Lopez, Antonio J.					maineabilm die kalencendementateriabilm specimentemen von deskription services und manufacture des regimen un von services und men des regimen und des regimentemen von services			US 6455043.	
56		Moon, James E. et al.		**************************************						US 6454938	
57		Casciari, . Joseph J. et al.								US 6448287	

	υ	1	Document ID	Issue Date	Page s	Title	Current OR	Current XRef
58	⊠		US 6448003 B1	2002091	30	Genotyping the human phenol sulfotransferbase 2 gene STP2	435/6	435/91.2 ; 536/23.2 ; 536/23.5 ;
59	⊠		US 6444638 B2	2002090	59	Combinations of PKC inhibitors and therapeutic agents for treating cancers	514/1	424/9.2; 514/151; 514/183; 514/245; 514/449; 514/90
60	⊠		US 6444427 B1	2002090	32	Polymorphisms in a diacylglycerol acyltransferase gene, and methods of use thereof	435/6	435/91.1 ; 435/91.2 ; 536/23.1
61	Ø		US 6433138 B1	2002081	47	Therapeutic and diagnostic methods and compositions based on jagged/notch proteins and nucleic acids	530/350	536/23.5
62	Ø		US 6432678 B1	2002081	11	Macaca cynomolgus IL 18	435/69.5 2	435/320. 1; 435/325; 435/69.1 ; 435/69.5 ; 530/324; 530/350;
63	⊠		US 6432639 B1	2002081	24	Isolated CYP3A4 nucleic acid molecules and detection methods	435/6	536/23.2 ; 536/23.5 ;
64	Ø		US 6432445 B1	2002081	6	Pharmaceutical capsules comprising a cyclosporin	424/455	424/451; 424/452; 424/456; 424/463
65	⊠		US 6432311 B1	2002081	52	Integrated monolithic microfabricated electrospray and liquid chromatography system and method	210/656	204/450; 210/198. 2; 210/243; 210/748; 250/288; 436/161

	Retriev al Classif	Inventor	s	С	P	2	3	4	5		mage Doc. Displayed	PT
58	·	Guida, Marco et al.								US	6448003	
59		Schwartz, Gary K. et al.								US	6444638	
60		Ludwig, Erwin H. et al.								US	6444427	
61		Zimrin, Ann B. et al.								US	6433138	
62		Taylor, Alexander H. et al.								US	6432678	
63		Lichter, Jay B. et al.								US	6432639	
64		Ambuhl, Michael et al.								US	6432445	
65		Moon, James E. et al.								US	6432311	

,

	υ	1	Document ID	Issue Date	Page s	Title	Current OR	Current XRef
66	Ø		US 6428790 B1	2002080	42	Cyanovirin conjugates and matrix-anchored cyanovirin and related compositions and methods of use	424/188. 1	424/140. 1; 424/178. 1; 424/184. 1; 424/484; 514/2
67	⊠		US 6420544 B1	2002071	13	Polynucleotide and polypeptide sequences encoding murine organic anion transporter 5 (mOATP5)	536/23.5	435/320. 1; 435/325; 435/69.1 ; 435/70.1
68	×		US 6420355 B2	2002071	8	Pharmaceutical compositions containing cyclosporins	514/200	514/937; 514/951
69	⊠		US 6420340 B2	2002071	24	Chemical modification of proteins to improve biocompatibility and bioactivity	514/12	514/2; 514/21; 530/324; 530/350; 530/391. 7; 530/402; 530/412
70	<b>⊠</b>		US 6420339 B1	2002071	20	Site-directed dual pegylation of proteins for improved bioactivity and	514/12	514/2; 514/909; 530/350; 530/402
71			US 6420336 B1	2002071	32	Methods of using cyanovirins topically to inhibit viral infection	514/2	424/159. 1; 424/160. 1; 424/430; 424/431; 424/432; 424/433; 424/436; 514/841; 530/300; 530/324; 530/350
72			US 6417510 B2	2002070	52	Integrated monolithic microfabricated electrospray and liquid chromatography system and method	250/288	204/600; 210/198. 2; 210/243; 210/656; 210/747

	Retriev al Classif	Inventor	s	С	P	2	3	4	5	Image Doc. Displayed	PT
66		Boyd, Michael R.								US 6428790	
67		Ellens, Harma et al.								US 6420544	
68		Richter, Friedrich et al.								US 6420355	
69		Gegg, Colin et al.								US 6420340	
70		Gegg, Colin et al.								US 6420339	
71		Boyd, Michael R.								US 6420336	
72		Moon, James E. et al.	V) 11 11 12 12 13 13 13 13 13 13 13 13 13 13 13 13 13	0				0		US 6417510	

	ט	1	Document ID	Issue Date	Page s	Title	Current OR	Current XRef
73		:	US 6416758 B1	2002070	108	Antibody conjugate kits for selectively inhibiting VEGF	424/145. 1	424/1.49; 424/1.53; 424/1.69; 424/133. 1; 424/134. 1; 424/135. 1; 424/141. 1; 424/142. 1; 424/178. 1; 424/179. 1; 424/181. 1; 424/183. 1; 424/195. 11; 424/9.2; 424/9.3; 435/69.6; ;
74	⊠		US 6410307 B1	2002062	8	Membrane module for testing active substances at cells	435/287. 1	435/297. 1; 435/297.
75	⊠		US 6410257 B1	2002062 5	33	Methods to assay gene function with viral vectors	435/29	435/320. 1; 435/456; 435/457; 536/23.1 ;
76	⊠		US 6407117 B1	2002061 8	19	Method of administering camptothecin compounds for the treatment of cancer with reduced side effects	514/283	424/717

	Retriev al Classif	Inventor	s	С	P	2	3	4	5		mage Doc. Displayed	PT
73		Thorpe, Philip E. et al.								US	6416758	
74		Glockner, Herma et al.								US	6410307	
75		Dropulic, Boro et al.						1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1		US	6410257	
76		Bouscarel, Bernard et al.						A man manifest to the control of the		US	6407117	

	υ	1	Document ID	Issue Date	Page s	Title	Current OR	Current XRef
77	⊠		US 6406715 B1	2002061	22	Intermediate release nicotinic acid compositions for treating hyperlipidemia having unique urinary metabolite profiles	424/468	424/464; 424/465; 424/470
78	⊠		US 6394942 B2	2002052 8	52	Integrated monolithic microfabricated electrospray and liquid chromatography system and method	438/712	438/689
79	×		US 6379882 B1	2002043	31	Method for selecting compounds for treating ischemia-related cellular damage	435/4	435/6; 435/7.8; 514/12; 514/13; 514/21; 514/29; 514/3; 514/35; 514/36; 514/37; 514/38; 514/46; 514/49; 530/399
80	⊠		US 6375990 B1	2002042	11	Method and devices for transdermal delivery of lithium	424/667	
81	⊠		US 6365373 B2	2002040	34	Nucleic acids encoding NGF variants	435/69.4	435/252. 3; 435/320. 1; 435/325; 536/23.5
82	⊠		US 6365185 B1	2002040 2	37	Self-destructing, controlled release peroral drug delivery system	424/473	424/464; 424/465; 424/466; 424/468; 424/469; 424/470; 424/471; 424/472

	Retriev al	Inventor	s	С	P	2	3	4	5		nage Doc.	PT
	Classif	Inventor			_	_				I	Displayed	
77		Cefali, Eugenio A.								US	6406715	
78		Moon, James E. et al.								US	6394942	
79		Bitler, Catherine M. et al.			0					US	6379882	
80		Nemeroff, Charles B. et al.		0						us	6375990	
81		Presta, Leonard G. et al.								US	6365373	100 til 100 til 100 til 100 til 100 til 100 til 100 til 100 til 100 til 100 til 100 til 100 til 100 til 100 ti
82		Ritschel, Wolfgang A. et al.								US	6365185	

	ט	1	Document ID	Issue Date	Page s	Title	Current OR	Current XRef
83			US 6361975 B1	2002032 6	13	Mouse aspartic secretase-2(mASP-2)	435/69.1	435/219; 435/320. 1; 435/325; 536/23.1; 536/23.2
84			US 6358725 B1	2002031	13	Mouse aspartic secretase-1 (mASP1)	435/212	435/252 3; 435/320 1; 435/325; 435/354; 536/23.2
85	⊠		US 6355465 B1	2002031	13	Compounds	435/194	435/252 3; 435/320 1; 435/7.1 536/23.2
86	×		US 6355265	2002031	20	Over-coated chewing gum formulations	424/440	424/464 424/48
87			US 6353019 B1	2002030	49	Macrocyclic lactones, compositions, and methods of use	514/450	549/270
88	⊠		US 6346233 B1	2002021	16	Composition for treating cancer via liposomal aerosol formulation containing taxol	424/45	424/450 424/46

	Retriev al Classif	Inventor	យ	C	Ą	2	3	4	5		mage Doc. Displayed	PT
83		Christie, Gary et al.								US	6361975	
84		Christie, Gary et al.								US	6358725	
85		Creasy, Caretha Lee et al.								US	6355465	
86		Ream, Ronald L. et al.								us	6355265	
87		Boyd, Michael R. et al.								US	6353019	
88		Knight, J. Vernon et al.								US	6346233	

•

	บ	1	Document ID	Issue Date	Page s	Title	Current OR	Current XRef
89			US 6342221 B1	2002012	107	Antibody conjugate compositions for selectively inhibiting VEGF	424/178.	424/1.49; 424/1.53; 424/130. 1; 424/179. 1; 424/181. 1; 424/183. 1; 424/195. 11; 424/9.3; 424/9.3; 424/9.34; 424/9.6; 435/7.1; 435/7.21; 435/7.21; 435/7.21; 435/7.21; 435/7.21; 435/7.21; 435/7.21; 435/7.21; 435/7.21; 435/7.21; 435/7.21; 435/7.21; 435/7.21; 435/7.21; 435/7.21; 435/7.21; 435/7.21; 435/7.21; 435/7.21;
90	⊠		US 6342220 B1	2002012 9	63	Agonist antibodies	424/153.	424/133. 1; 424/135. 1; 530/387. 1; 530/388.

	Retriev	Inventor	s	С	P	2	3	4	5	Image Doc.	РT
L	Classif			<u></u>						Displayed	
89		Thorpe, Philip E. et al.								US 6342221	
90		Adams, Camellia W. et al.								US 6342220	

	ט	1	Document ID	Issue Date	Page s	Title	Current OR	Current XRef
91			US 6342219 B1	2002012	106	Antibody compositions for selectively inhibiting VEGF	424/145. 1	424/133. 1; 424/134. 1; 424/135. 1; 424/141. 1; 424/142. 1; 424/143. 1; 435/335; 435/69.1; 435/810; 530/387. 1; 530/387. 3; 530/388. 1; 530/388. 1; 530/391. 1; 530/391. 3; 530/391. 5;
92			US 6339107 B1	2002011	9	Methods for treatment of Emphysema using 13-cis retinoic	514/725	424/45
93	×		US 6335316 B1	2002010	12	Method for administering acylated insulin	514/3	514/12; 530/300; 530/324
94	Ø		US 63333310 B1	2001122	38	NGF variants	514/12	514/2; 530/350; 530/399
95			US 6329153 B1	2001121	13	Method for evaluating immunosuppressive regimens	435/7.1	435/355; 435/366; 435/372; 435/7.2; 435/7.92 ; 436/512;

	Retriev al Classif	Inventor	s	С	P	2	3	4	5		mage Doc. Displayed	PT
91		Thorpe, Philip E. et al.								US	6342219	
92		Belloni, Paula N			0					US	6339107	
93		Hughes, Benjamin Lee et al.						٥		US	6335316	
94		Presta, Leonard G. et al.								US	6333310	
95		Stein, Charles M. et al.			0					US	6329153	

	ט	1	Document ID	Issue Date	Page s	Title	Current OR	Current XRef
96	⊠		US 6322806 B1	2001112 7	22	Over-coated chewing gum formulations including tableted center	424/440	424/464; 424/48
97	⊠		US 6319678 B1	2001112	10	Process for glucuronidation screening	435/15	435/14; 435/18; 435/4
98	⊠		US 6307024 B1	2001102 3	105	Cytokine zalpha11 Ligand	530/351	424/143. 1; 424/145. 1; 435/69.1 ; 435/69.7
99	⊠		US 6306820 B1	2001102	36	Combination therapy using a TNF binding protein for treating TNF-mediated	514/2	530/350
100			US RE37410 E	2001101	22	Controlled local delivery of chemotherapeutic agents for treating solid tumors	424/484	424/401; 424/426; 424/486; 424/499
101	⊠		US 6302838	2001101	29	Cancer treatment with epothilones	514/365	
102			US 6294199 B1	2001092	18	Method of treating a bacterial infection comprising administering amoxycillin	424/468	424/400; 424/441; 424/451; 424/464; 424/466; 424/470; 424/472; 424/482; 424/489
103			US 6291439 B1	2001091	26	Methods for diagnosing atherosclerosis by measuring endogenous heparin and methods for treating atherosclerosis	514/56	204/452; 204/603
104			US 6291223 B1	2001091	13	Mouse aspartic secretase-1 (mASP1)	435/212	435/219; 435/252. 3; 435/320. 1; 435/325; 435/354; 536/23.2

	Retriev	Inventor	s	С	P	2	3	4	5		mage Doc. Displayed	PT
96	Classif	Ream, Ronald L. et al.									6322806	
97		Trubetskoy, Olga et al.			0					US	6319678	
98		Novak, Julia E. et al.								US	6307024	
99		Bendele, Alison M. et al.								US	6306820	
100		Brem, Henny et al.								us	RE37410	
101		O'Reilly, Terence et al.								us	6302838	
102		Conley, Creighton P. et al.								US	6294199	
103		Klock, John C.								US	6291439	
104		Christie, Gary et al.							П	US	6291223 .	

	U	1	Document ID	Issue Date	Page s	Title	Current OR	Current XRef
105	Ø		US 6287537 B1 .	2001091	35	Radioimmunotherapy of lymphoma using anti-CD20 antibodies	424/1.49	424/1.53; 424/144. 1; 424/155. 1; 530/387. 3; 530/387. 7; 530/388. 1;
106	×		US 6284786 B1	2001090 4	5	Treatment of cancer using lipoic acid in combination with ascorbic acid	514/440	
107			US 6284267 B1	2001090 4	40	Amphiphilic materials and liposome formulations thereof	424/450	424/1.21; 424/417; 424/9.32 1; 424/9.51; 424/94.3; 428/402. 2; 436/829; 554/103; 554/227;
108	⊠		US 6271195 B1	2001080 7	43	Aminimide-containin g molecules and materials as molecular recognition agents	514/1	526/307; 527/200
109	×		US 6268335 B1	2001073	32	Insoluble insulin compositions	514/3	424/491; 514/4; 530/303; 530/304; 530/345
110	⊠		US 6262022 B1	2001071 7	12	Pharmaceutical compositions containing cyclosporin as the active agent	514/11	514/937; 514/938; 514/943; 554/207
111	×		US 6258808	2001071 0	13	Pharmaceutical composition	514/552	514/962

	Retriev al Classif	Inventor	s	С	P	2	3	4	5		mage Doc. Displayed	PT
105		Kaminski, Mark S. et al.								US	6287537	
106		Casciari, Joseph J. et al.								US	628478 <u>6</u>	
107		Aneja, Rajindra								US	6284267	
108		Hogan, Jr., Joseph C.								us	6271195	
109		Brader, Mark Laurence								us	6268335	
110		Hauer, Birgit et al.								US	6262022	
111		Hauer, Birgit et al.								us	6258808	а

	σ	1	Document ID	Issue Date	Page s	Title	Current OR	Current XRef
112	⊠		US 6251388 B1	2001062 6	24	Utilization of Wolinella succinogenes asparaginase to treat diseases associated with asparagine dependence	424/94.6	435/229; 435/252. 3; 435/320. 1; 536/23.2
113	⊠		US 6245737 B1	2001061	31	Conjugates of antiviral proteins or peptides and virus or viral envelope glycoproteins	514/2	435/69.1; 435/69.7; 514/12; 514/13; 514/14; 514/15; 514/8; 530/350; 530/395; 530/402.
114	⊠		US 6245227 B1	2001061	56	Integrated monolithic microfabricated electrospray and liquid chromatography system and method	210/198. 2	204/600; 210/243; 210/656; 210/748; 250/288
115	⊠		US 6239124 B1	2001052 9	10	Pharmaceutical compositions for the treatment of transplant rejection or autoimmune or inflammatory conditions comprising cyclosporin A and 40-0-(2-hydroxyethy 1)-ranamycin	514/183	514/514
116	⊠		US 6232120 B1	2001051	31	Methods to inhibit replication of infective virus	435/375	435/320. 1; 435/457; 435/458; 514/44
117	⊠		US 6224550 B1	2001050	12	Method for monitoring the level of an osmotically active component in body fluid and device for carrying out said method	600/366	204/403. 06; 204/415; 205/778; 600/345; 600/373; 600/573; 600/584

	Retriev al Classif	Inventor	s	С	P	2	3	4	5	Image Doc. Displayed	PT
112		Durden, Donald L.								US 6251388	
113		Boyd, Michael R. et al.								US 6245737	
114		Moon, James E. et al.								US 6245227	
115		Zenke, Gerhard et al.								US 6239124	
116		Dropulic, Boro et al.								US 6232120	
117		Ellingsen, Olav								US 6224550	

	υ	1	Document ID	Issue Date	Page s	Title	Current OR	Current XRef
118	Ø		US 6207426 B1	2001032	32	Conditionally replicating viral vectors and their use	435/91.4 1	435/320. 1; 435/91.4
119	⊠		US 6204247 B1	2001032	21	Chemical modification of proteins to improve biocompatibility and bioactivity	514/12	514/2; 514/21; 530/324; 530/402; 530/412
120	×		US 6203790 B1	2001032	55	Platelet-activating factor acetylhydrolase	424/94.6	
121	⊠		US 6200566 B1	2001031	18	Anti-endoglin monoclonal antibodies and their use in antiangiogenic therapy	424/130. 1	424/133. 1; 424/141. 1; 424/142. 1; 530/350
122	⊠	The state of the s	US 6197575 B1	2001030	46	Vascularized perfused microtissue/micro-o rgan arrays	435/288. 4	435/288. 7; 435/297. 5; 435/305. 2; 435/33; 435/373; 435/395
123	⊠		US 6194579 B1	2001022	17	Highly lipophilic camptothecin derivatives	546/48	
124	×		US 6194391 B1	2001022	31	3'-azido-2',3'-dide oxyuridine administration to treat HIV and related test protocol	514/50	435/6; 514/253. 01; 514/263. 23; 514/45; 514/46; 514/47; 514/48; 514/49; 514/51
125	⊠	11. III. III. III. III. III. III. III.	US 6193982 B1	2001022	38	Anti-cyanovirin antibody with an internal image of gp120, a method of use thereof, and a method of using a cyanovirin to induce an immune response to gp120	424/208. 1	424/185. 1; 424/188. 1; 435/327; 435/331; 436/548; 530/350; 536/23.7

	Retriev al Classif	Inventor	s	С	P	2	3	4	5		ge Doc. splayed	PT
118	:	Dropulic, Boro et al.								US 62	07426	
119		Gegg, Colin et al.								US 62	04247	
120		Cousens, Lawrence S. et al.								US 62	03790	
121		Seon, Ben K.								US 62	00566	
122		Griffith, Linda G. et al.				·				US 61	97575	
123		Hausheer, Frederick H.								US 61	94579	
124		Schinazi, Raymond F. et al.		` ·						US 61:	94391	
125		Boyd, Michael R.						-	,	US 61	93982	

	U	1	Document ID	Issue Date	Page s	Title	Current OR	Current XRef
126	⊠		US 6190660 B1	2001022	29	Anti-endoglin monoclonal antibodies and their use in antiangiogenic therapy	424/130. 1	424/133. 1; 424/141. 1; 424/142. 1; 530/350
127	Ø		US 6174882 B1	2001011 6	7	2-hydroxymethylolan zapine compositions and methods	514/220	540/557
128	⊠		US 6174684 B1 `	2001011 6	12	CYP3A4 NFSE variant and methods of use therefore	435/6	435/91.1 ; 435/91.2 ;
129	⊠		US 6169166 B1	2001010 2	13	Polynucleotide and polypeptide sequences encoding rat mdr1b2 and screening methods thereof	530/350	
130	⊠	ŧ —	US 6168953 B1	2001010 2	31	Genetic antiviral agents and methods for their use	435/455	435/320. 1; 435/325; 435/457; 435/91.3 1; 514/44; 536/23.1 ;
131	Ø		US 6168795 B1	2001010	10	Method for anticancer therapy using an herbal extract composition	424/729	
132	Δ		US 6156731 A	2000120	15	Polypeptide composition for oral administration	514/15	424/185. 1; 424/464; 514/12; 514/13; 514/14; 514/2; 530/300; 530/311; 530/324; 530/326; 530/327; 530/328
133	⊠		US 6147095 A	2000111 4	20	Method for improving the pharmacokinetics of	514/336	

	Retriev	Inventor	s	С	P	2	3	4	5	Image Doc. Displayed	PT
126	Classif	Seon, Ben K.								US 6190660	
127		Yelle, William E.								US 6174882	
128		Rebbeck, Timothy R. et al.								US 6174684	
129		Brun, Kimberly A. et al.								US 6169166	
130		Dropulic, Boro et al.								US 6168953	0
131		DJang, Arthur H. K.			0	0				US 6168795	
132		Grass, George M. et al.								US 6156731	
133		Ferry, James J. et al.								US 6147095	

	υ	1	Document	Issue Date	Page s	Title	Current OR	Current XRef
134	Ø		US 6146625 A	2000111	57	Platelet-activating factor acetylhydrolase	424/94.6	
135	. ⊠		US 6143325 A	2000110	9	Nefazodone dosage form	424/468	424/464; 424/474; 424/480; 514/254. 05; 514/255. 03; 514/384
136	⊠		US 6136801 A	2000102	15	Therapeutic agent with quantitative consumption marker	514/220	436/111; 436/112; 436/163; 436/808; 436/901
137	Ø		US 6117859 A	2000091	11	Method of relieving chronic inflammation by using 5-alkylsulfonylsali	514/166 <sub>.</sub>	
138	⊠		US 6114141 A	2000090	39	Methods to express genes from viral vectors	435/69.1	435/320. 1; 435/457; 435/91.3 1; 514/44; 536/24.5
139	×		US 6099836 A	2000080	57	Platelet-activating factor acetylhydrolase (PAF-AH) therapeutic uses	424/94.6	435/195; 435/196; 435/197
140	×		US 6096728 A	2000080	28	Composition and method for treating inflammatory diseases	514/62	530/351
141	⊠		US 6096725 A	2000080	37	Methods of using .alpha.Gal oligosaccharides as immune system targeting agents	514/53	424/137. 1; 514/54; 514/62
142	×		US 6090407 A	2000071	24	Small particle liposome aerosols for delivery of anti-cancer drugs	424/450	424/45; 514/938

	Retriev								_			
	al Classif	Inventor	ន	С	P	2	3	4	5		mage Doc. Displayed	PT
134		Cousens, Lawrence S. et al.								US	6146625	
135		Dennis, Andrew B. et al.								US	6143325	
136		Kell, Michael								US	6136801	
137		Evans, Richard T. et al.								US	6117859	
138		Dropulic, Boro et al.								US	6114141	
139		Cousens, Lawrence S. et al.								US	6099836	
140		Collins, David S. et al.								US	6096728	
141		Simon, Paul M. et al.								US	6096725	
142		Knight, J. Vernon et al.								US	6090407	

	U	1	Document ID	Issue Date	Page s	Title	Current OR	Current XRef
143	×		US 6090365 A	2000071	34	Radioimmunotherapy of lymphoma using anti-CD20 antibodies	424/1.49	424/1.53; 424/143. 1; 424/144. 1; 424/154. 1;
144	×		US 6083923 A	2000070	43	Liposomal oligonucleotide compositions for modulating RAS gene expression	514/44	435/375; 435/377; 435/455; 435/6; 536/23.1 ; 536/24.1
145	Ø		US 6077537 A	2000062	30	Non-sedating acrivastine product	424/468	424/457; 514/290; 514/778
146	Ø		US 6066668 A	2000052	23	Formulations and methods of reducing toxicity of antineoplastic agents	514/492	424/649; 514/772
147	Ø		US 6066645 A	2000052	22	Formulations and methods of reducing toxicity of antineoplastic agents	514/283	514/285; 514/463; 514/772; 514/946; 514/947
148			US 6066091 A	2000052	26	Methods, systems and products for determining drug withdrawal	600/300	128/898; 128/920
149			US 6057361 A	2000050	22	Formulations and methods of reducing toxicity of antineoplastic agents	514/460	514/649; 514/772; 514/946; 514/947
150	⊠		US 6054490 A	2000042	13	Use of sesquiterpenes for inhibiting oxidative enzymes	514/675	514/724; 514/762; 514/763; 514/766; 568/303
151	Ø		US 6051551 A	2000041	12	Method for administering acylated insulin	514/3	514/12; 530/324

	<del>,</del>								_	<b>)</b>		
	Retriev al Classif	Inventor	ន	C	P	2	თ	4	5		mage Doc. Displayed	PT
143		Kaminski, Mark S. et al.		D						US	6090365	
144		Hardee, Gregory E. et al.								US	6083923	
145		Booth, Anthony et al.							0	US	6077537	
146		Hausheer, Frederick H. et al.								US	6066668	
147		Hausheer, Frederick H. et al.								us	6066645	
148		Riviere, Jim E. et al.	⊠							US	6066091	
149		Hausheer, Frederick H. et al.	⊠							US	6057361	
150		Sime, John Thomas et al.								US	6054490	
151		Hughes, Benjamin Lee et al.								us	6051551	

	υ	1	Document ID	Issue Date	Page s	Title	Current OR	Current XRef
152	⊠		US 6048849 A	2000041	22	Formulations and methods of reducing toxicity of antineoplastic agents	514/178	514/182; 514/284; 514/328; 514/365; 514/453; 514/555; 514/626; 514/648; 514/733; 514/772; 514/946; 514/947
153	⊠		US 6046234 A	2000040 4	23	Formulations and methods of reducing toxicity of antineoplastic agents	514/517	514/589; 514/672; 514/772; 514/946; 514/947
154	⊠	_	US 6046159 A	2000040 4	22	Formulations and methods of reducing toxicity of antineoplastic agents	514/2	514/21; 514/23; 514/450; 514/475; 514/577; 514/575; 514/748; 514/772; 514/946; 514/947
155	×		US 6045815 A	2000040 4	28	Parenteral pimaricin as treatment of systemic infections	424/405	424/406; 514/31; 514/937; 514/943
156	×		US 6045794 A	2000040 4	69	Platelet-activating factor acetylhydrolase	424/94.6	435/195; 514/2; 530/350; 530/380
157	⊠		US 6043249 A	2000032 8 ·		Formulations and methods of reducing toxicity of antineoplastic agents	514/266. 1	514/772; 514/946; 514/947
158	⊠		US 6042822 A	2000032 8	14	Interferon polymer conjugates	424/85.7	530/351; 530/409; 530/410; 530/411
159	Ø		US 6040312 A	2000032	23	Formulations and methods of reducing toxicity of antineoplastic agents	514/283	514/772; 514/946; 514/947

	Retriev al Classif	Inventor	s	С	P	2	3	4	5		age Doc. Displayed	PT
152		Hausheer, Frederick H. et al.								US (	6048849	
153		Hausheer, Frederick H. et al.								US	6046234	
154		Hausheer, Frederick H. et al.								US	6046159	
155		Andersson, Borje S. et al.								us	6045815	
156		Cousens, Lawrence S. et al.								US	6045794	
157		Hausheer, Frederick H. et al.								US	6043249	
158		Gilbert, Carl W. et al.								us	6042822	
159		Hausheer, Frederick H. et al.								US	6040312	

	ט	1	Document ID	•	Issue Date	Page s	Title	Current OR	Current XRef
160	×	0	US 6040304 <i>I</i>	- 1	2000032	22	Formulations and methods of reducing toxicity of antineoplastic agents	514/221	514/413; 514/459; 514/772; 514/946; 514/947
161	⊠		US 6040294 <i>I</i>		2000032 1	22	Formulations and methods of reducing toxicity of antineoplastic agents	514/23	514/263. 31; 514/274
162	Ø		US 6030636 <i>I</i>		2000022 9	23	Calcium sulfate controlled release matrix	424/426	424/489; 514/951
163	×		US 6028078 <i>I</i>		2000022 2	18	Highly lipophilic camptothecin derivatives	514/283	546/48
164	Ø		US 6025488 <i>I</i>	A	2000021 5	21	Formulations and methods of reducing toxicity of antineoplastic agents	540/454	
165	×		US 6025160 Z	A	2000021 5	17	Polynucleotide and polypeptide sequences encoding rat mdr1b2 and screening methods thereof	435/69.1	435/252. 3; 435/254. 2; 435/320. 1; 435/325; 435/348; 435/410; 536/23.1
166	×		US 6017876 <i>i</i>		2000012 5	26	Chemical modification of granulocyte-colony stimulating factor (G-CSF) bioactivity	514/8	514/2; 514/21; 530/324; 530/402; 530/412
167	Ø		US 6015876	A	2000011 8	31	Method of using cyanovirins	530/300	530/350
168	⊠		US 6015542	Α	2000011	30	Radioimmunotherapy of lymphoma using anti-CD20 antibodies	424/1.49	424/1.53; 424/174. 1; 530/388. 73; 530/391. 3;
169	Ø	0	US 6000828	A	<u></u>	24	Method of improving drug treatment	705/2	
170	⊠		US 5998587	A	1999120 7	36	Anti-cyanovirin antibody	530/387. 9	530/389. 4

	Retriev al Classif	Inventor	ល	С	P	2	3	4	5		mage Doc. Displayed	PT
160		Hausheer, Frederick H. et al.								US	6040304	
161		Hausheer, Frederick H. et al.								US	6040294	
162		Randolph, Donald A. et al.								us US	6030636	
163		Hausheer, Frederick H. et al.								US	6028078	
164		Hausheer, Frederick H.			D	D				us	6025488	
165		Brun, Kimberly A et al.								US	6025160	
166		Gegg, Colin et al.								US	6017876	
167		Boyd, Michael R.								US	6015876	
168		Kaminski, Mark S. et al.								US	6015542	
169		Leet, Larry								US	6000828	
170		Boyd, Michael R. et al.								US	5998587	

	ט	1	Document ID	t	Issue Date	Page s	Title	Current OR	Current XRef
171			US 5989918	A	1999112 3	8	ADME analysis of mixtures	436/63	435/1.1; 435/1.2; 436/124; 436/503; 514/743; 514/746; 514/746; 514/759; 514/832; 604/4.01
172	⊠		US 5985307	A	1999111 6	23	Device and method for non-occlusive localized drug delivery	424/423	604/103. 07; 604/264; 604/523; 604/530
173	⊠		US 59852 <sub>6</sub> 5	Α	1999111 6	29	N-terminally chemically modified protein compositions and methods	424/85.4	424/85.1; 424/85.5; 424/85.6; 424/85.7; 514/12; 514/2;
174	Ø		US 5981467	Α	1999110 9	44	Aminimide-containin g molecules and materials as molecular recognition agents	514/1	
175	Ø		US 5977308	A	1999110 2	65	Platelet-activating factor acetylhydrolase	530/350	530/300; 536/23.1 ;
176	×		US 5965126	Α	1999101 2	25	use of mutant alkyltransferases for gene therapy to protect from toxicity of therapeutic alkylating agents	424/93.2 1	435/320. 1; 435/325; 435/455; 435/69.5 ; 514/44;
177	Ø		US 5962668	Α	1999100	33	Nucleic acids encoding antiviral proteins and peptides fused to effector proteins	536/23.4	536/23.1 ; 536/23.7 2
178			US 5962653	Α	1999100 5	30	Methods of obtaining antiviral proteins and antiviral peptides from Nostoc	530/417	530/412

	Retriev al Classif	Inventor	S	С	P	2	3	4	5		nage Doc. Displayed	PT
171		Dietz, Corine M. et al.	×							US	5989918	
172		Hanson, Stephen R. et al.						٥		US	5985307	
173		Kinstler, Olaf B. et al.								US	5985265	
174		Hogan, Jr., Joseph C.								US	5981467	
175		Cousens, Lawrence S. et al.				0		0		us	5977308	
176		Pegg, Anthony E. et al.								US	5965126	
177		Boyd, Michael R. et al.							Ō	US	5962668	
178		Boyd, Michael R. et al.								us	5962653	

							·	·
	ָּט	1	Document ID	Issue Date	Page s	Title	Current OR	Current XRef
179	Ø		US 5961952 A	1999100	8	.sup.99m Tc-tertiary-butyl isonitrile as breast tumor	424/1.65	424/1.11 ; 424/9.1; 534/14
180	⊠		US 5958911 A	1999092 8	8	Method of relieving inflammation by using 5-alkylsulfonylsali cylanilides	514/166	
181	Ø		US 5951974 A	1999091 4	14	Interferon polymer conjugates	424/85.7	530/351; 530/409; 530/410; 530/411
182	×		US 5948780 A	1999090 7	52	Method for treating and preventing heart failure and ventricular dilatation	514/255. 01	514/255. 03; 514/317; 514/454; 514/561; 514/562
183	×		US 5942248 A	1999082	12	Pharmaceutical composition containing a low detergent effect bile salt and an active compound that undergoes biliary excretion and/or enterohepatic	424/457	424/468; 424/469; 424/474; 424/475
184	×		US 5932243 A	1999080	9	Galenical formulations	424/450	424/400; 514/11; 514/937; 514/938
185	⊠		US 5928641 A	1999072 7	19	Anti-endoglin monoclonal antibodies and their use in antiangiogenic therapy	424/130. 1	424/133. 1; 424/141. 1; 424/142. 1; 530/350

	Retriev al Classif	Inventor	s	U	P	2	3	4	5	Image Doc. Displayed	PT
179		Crane, Paul David et al.								US 5961952	
180		Evans, Richard T. et al.								US 5958911	
181		Gilbert, Carl W. et al.								US 5951974	
182		Peterson, Jr., Joseph Thomas et al.								US 5948780	
183		Barnwell, Stephen George								US 5942248	
184		Fricker, Gerd et al.								US 5932243	
185		Seon, Ben K.								US 5928641	

•

	υ	1	Document Issue Page Title Date s					Current XRef
186			US 5919816 A	1999070	22	Formulations and methods of reducing toxicity of antineoplastic agents	514/449	514/100; 514/108; 514/107; 514/127; 514/128; 514/221; 514/241; 514/263. 3; 514/264. 11; 514/266. 4; 514/266. 4; 514/283; 514/283; 514/283; 514/283; 514/283; 514/283; 514/266; 514/274; 514/283; 514/283; 514/283; 514/283; 514/283; 514/283; 514/283; 514/456; 514/456; 514/450; 514/507; 514/507; 514/507; 514/615; 514/649; 514/649; 514/672; 514/83
187	×	0	US 5917090 A	1999062 9	12	Matrix metalloproteinase inhibitors	562/623	562/621
188	Ø		US 5910491 A	1999060 8	21	Highly lipophilic camptothecin derivatives	514/63	514/283; 544/238; 546/14; 546/48
189	×		US 5902610 A	1999051 1	25	Formulations and methods of use of 2,2'-dithio-bis-eth ane sulfonate	424/649	514/274; 514/283
190	⊠		US 5900404 A	1999050 4	21	Chemical modification of proteins to improve biocompatibility and bioactivity	514/12	514/2; 530/324; 530/402; 530/412

	Retriev al Classif	Inventor	s	С	P	2	3	4	5		mage Doc. Displayed	PT
186		Hausheer, Frederick H. et al.								US	5919816	
187	i	Huxley, Philip et al.								US	5917090	
188		Hausheer, Frederick H. et al.								US	5910491	
189		Hausheer, Frederick Herman et al.								US	5902610	
190		Gegg, Colin et al.								US	5900404	